We found no evidence of lineage/histology changes as a source of acquired resistance in evaluable patients (three RET fusion-positive lung cancers) who developed drug resistance without an identified clear genetic driver where a post-progression biopsy was available (Supplemental Fig. 9). This evidence concerns the gene RET and lung cancer.